The Healthcare Systems Research Network (HCSRN) as an Environment for Dissemination and Implementation Research: A Case Study of Developing a Multi-Site Research Study in Precision Medicine by Rahm, Alanna Kulchak et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Articles Open Access Publications by UMMS Authors 
2019-04-12 
The Healthcare Systems Research Network (HCSRN) as an 
Environment for Dissemination and Implementation Research: A 
Case Study of Developing a Multi-Site Research Study in Precision 
Medicine 
Alanna Kulchak Rahm 
Geisinger 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Health and Medical Administration Commons, Health Services Administration Commons, 
Health Services Research Commons, and the Therapeutics Commons 
Repository Citation 
Rahm AK, Ladd I, Burnett-Hartman AN, Epstein MM, Lowery JT, Lu CY, Pawloski PA, Sharaf RN, Liang S, 
Hunter JE. (2019). The Healthcare Systems Research Network (HCSRN) as an Environment for 
Dissemination and Implementation Research: A Case Study of Developing a Multi-Site Research Study in 
Precision Medicine. Open Access Articles. https://doi.org/10.5334/egems.283. Retrieved from 
https://escholarship.umassmed.edu/oapubs/3824 
Creative Commons License 
This work is licensed under a Creative Commons Attribution 4.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles 
by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
Rahm, AK, et al. 2019 The Healthcare Systems Research Network (HCSRN) as an Environment 
for Dissemination and Implementation Research: A Case Study of Developing a Multi-Site 
Research Study in Precision Medicine. eGEMs (Generating Evidence & Methods to improve 
patient outcomes), 7(1): 16, pp. 1–9. DOI: https://doi.org/10.5334/egems.283
CASE STUDY
The Healthcare Systems Research Network (HCSRN) as 
an Environment for Dissemination and Implementation 
Research: A Case Study of Developing a Multi-Site 
Research Study in Precision Medicine
Alanna Kulchak Rahm1, Ilene Ladd1, Andrea N. Burnett-Hartman2, Mara M. Epstein3,  
Jan T. Lowery4, Christine Y. Lu5, Pamala A. Pawloski6, Ravi N. Sharaf7, Su-Ying Liang8 
and Jessica Ezzell Hunter9
1 Geisinger, US
2 Kaiser Permanente Colorado, Institute for Health Research, US
3 The Meyers Primary Care Institute and Department of Medicine, University of Massachusetts Medical School, US
4 University of Colorado, US
5 Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, US
6 HealthPartners Institute, US
7 Weill Cornell Medicine, US
8 Palo Alto Medical Foundation Research Institute, US
9 Kaiser Permanente Northwest, US
Corresponding author: Alanna Kulchak Rahm, PhD, MS, LGC (akrahm@geisinger.edu)
Context: In existence for nearly 25 years, the Healthcare Systems Research Network (HCSRN) is an 
established and sustainable network of health care systems that serves as a “real world” laboratory to 
enable the integration of research findings into practice. The objective of this paper is to demonstrate 
how the HCSRN serves as an ideal environment for studying dissemination and implementation of evidence-
based practices into health care systems through the example of developing a multi-site study on the 
implementation of evidence-based precision medicine practices.
Case description: The “Implementing Universal Lynch Syndrome Screening (IMPULSS)” study (NIH 
R01CA211723) involves seven HCSRN health care systems and two external health care systems. The 
IMPULSS study will describe and explain organizational variability around Lynch syndrome (LS) screening 
to identify which factors in different organizational contexts are important for successful implementation 
of LS screening programs and will create a toolkit to facilitate organizational decision making around 
implementation and improvement of precision medicine programs in health care systems.
Major Themes: The strengths of the HCSRN that facilitate D&I research include: 1) a culture of collaboration, 
2) standardization of data and processes across systems, and 3) researchers embedded in diverse health 
care systems. We describe how these strengths contributed to developing the IMPULSS study.
Conclusion: Given the importance of conducting research in real world settings to improve patient 
outcomes, the unique strengths of the HCSRN are of vital importance. The IMPULSS study is one case 
example of how the strengths of the HCSRN make it an excellent environment for research on implementing 
evidence-based precision medicine practices in health care systems.
Keywords: HCSRN; Lynch syndrome; Dissemination and implementation; implementation science; precision 
medicine
Context
Established in 1994, the Healthcare Systems Research Network (HCSRN) is a network of over 1,900 researchers across 19 
health care systems who regularly collaborate and serve as a research laboratory based in “real-world” health care popu-
lations and environments and to enable the rapid integration of research findings into practice [1]. In this paper, we 
present a case study that leverages the strengths of the HCSRN for dissemination and implementation science research. 
The objective of this paper is to demonstrate how the HCSRN serves as an ideal environment for studying dissemination 
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and implementation of evidence-based practices into health care systems through the example of developing a multi-
site study on the implementation of evidence-based precision medicine practices into diverse health care systems.
Definition of Dissemination and Implementation
The implementation of effective technologies and evidence-based precision medicine strategies into clinical practice 
is challenging and slow and contributes to variability and deficiencies in quality of care [2, 3]. Contextual factors, such 
as organization mission and structure, economic considerations, provider preferences and readiness, as well as patient 
population and attitudes, influence implementation decisions within individual health care systems [4–6].
Dissemination and implementation (D&I) science bridges the gap between research and clinical practice by generat-
ing evidence to: 1) understand how evidence spreads to different stakeholders in the health care system (dissemination) 
and 2) characterize how the behavior and perspectives of clinical stakeholders, health care organizations, and patients 
influence the adoption, adaptation, and sustainability of evidence-based practices in real world settings (implementa-
tion) [4, 7].
The HCSRN for D&I Research
The HCSRN provides an optimal environment to conduct D&I studies. The HCSRN will celebrate its 25th year of embed-
ded research in health care systems in 2019; therefore is also an established and sustainable network in which to 
conduct D&I research. The “real-world” health care organizational infrastructure, clinical infrastructure, providers, and 
patient populations within the HCSRN represent diverse contextual factors to better understand the factors influencing 
dissemination and implementation of evidence-based practices.
Overall, the HCSRN member systems provide care for over 28 million individuals based in diverse geographic regions 
across 13 states (Figure 1). All HCSRN health care systems have robust electronic health record (EHR) systems as well 
as researchers embedded within the health care system and experienced in utilizing and interpreting the extensive 
EHR data. HCSRN systems have adopted a common data model, standardized administrative processes and procedures 
for collaborations with external researchers and organizations, as well as templates and best practices for data use 
agreements (DUAs) and for institutional review board (IRB) ceding to a single institution in order to facilitate multi-site 
research more efficiently and effectively.
In this paper, we present the case of developing a research study that leverages the HCSRN for D&I research in pre-
cision medicine. This multi-site project is a collaboration between seven systems across the HCSRN and two external 
Figure 1: Map of HCSRN with IMPULSS Study Sites Highlighted.
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organizations whose collaboration in the project was facilitated through the HCSRN. Due in part to the strengths of the 
HCSRN for D&I research, this project was subsequently funded by the National Institutes of Health (NIH).
Case description: developing a research project in the HCSRN for D&I research
Benefits of conducting D&I science within the HCSRN can be illustrated through the example of the newly-funded 
study, “Implementing Universal Lynch Syndrome Screening (IMPULSS)” [8]. The IMPULSS study is a multi-site R01 that 
was submitted under the Program Announcement for Dissemination and Implementation in Health (DIRH) (PAR-18-
007) and subsequently funded in July, 2017 by the National Institutes of Health (NIH) through the Beau Biden Cancer 
Moonshot funds (NIH R01CA211723).
The health care systems participating in IMPULSS were identified through collaborations facilitated by the HCSRN, 
the HCSRN Genomics Scientific Interest Group (SIG), and the Cancer Research Network (CRN). Seven HCSRN health care 
systems are participating in the IMPULSS study (Geisinger, Kaiser Permanente Northwest (KPNW), KP Colorado (KPCO), 
HealthPartners, Harvard Pilgrim Health Care, Sutter Health-Palo Alto Medical Foundation, and Meyers Primary Care 
Institute). Two non-HCSRN organizations (Catholic Health Initiatives and Weill Cornell Medicine) are also collaborating 
in the IMPULSS study (Figure 1).
Both non-HCSRN organizations were identified through existing collaborations with the HCSRN: the IMPULSS site 
principal investigator (PI) from Weill Cornell Medicine has an established record of collaboration within the HCSRN 
related to Lynch Syndrome through the CRN Scholar program [9]. An IMPULSS investigator associated with Catholic 
Health Initiatives was an active participant in the HCSRN Genomics SIG, through which the IMPULSS study was created.
Preliminary data for the IMPULSS project were gathered by surveying the two non-HCSRN organizations and all 
HCSRN organizations about their respective Lynch Syndrome screening practices in general. The application for fund-
ing was developed through a collaborative process which included the overall PI presenting the IMPULSS project con-
cept in multiple HCSRN venues to identify researchers interested in collaboration. The administrative requirements 
(sub-award budgets, facilities and infrastructure, and planned enrollment tables) were efficiently facilitated through 
processes developed through the long-standing collaborations within the HCSRN to gather and share such materials for 
grant applications. This familiarity of administrative processes enabled the application process to run efficiently with 
the seven HCSRN sites so that administrative staff at the prime institution could focus on any procedural needs that 
arose with the non-HCSRN sites.
Lynch Syndrome Screening and Contextual Differences Facilitating D&I Research
Lynch Syndrome (LS) is the most common form of inherited colorectal cancer and is also associated with significant risk 
for endometrial, ovarian, gastric, small bowel, and renal cancers, among others [10, 11]. LS is characterized by muta-
tions in mismatch repair genes and is inherited in an autosomal dominant pattern. Estimates indicate about 1 million 
people in the United States have LS [12, 13]. LS accounts for 3–5 percent of all newly diagnosed CRC [10]; yet only 
about 2 percent of such individuals are identified as having the condition [13]. Universal Lynch syndrome screening is 
the systematic screening of all newly diagnosed cases of colorectal and endometrial cancers to identify patients whose 
cancer is related to LS [14]. LS screening includes evaluating tumors for mismatch repair gene deficiency and offering 
genetic counseling and confirmatory germline genetic testing to individuals who screen positive. LS screening is one of 
the first cost-effective [15, 16] genomic medicine interventions with evidence [17] for saving lives and improving qual-
ity of life [18]. LS screening was first recommended by the Evaluation of Genetic Application in Practice and Prevention 
(EGAPP) working group in 2009 [14, 19], is currently recommended by multiple professional organizations [10, 20–24], 
is endorsed by the National Comprehensive Cancer Network (NCCN) [25], the Centers for Disease Control (CDC), and is 
an objective of the Healthy People 2020 initiative [26]. In September 2016, the Blue Ribbon Panel Report recommended 
LS screening as a high priority intervention with the potential to achieve the goals of the Cancer Moonshot [12].
Implementing LS screening in health care systems, however, involves multiple stakeholders and customization to 
local contextual factors, including integrating LS screening into individual organizational processes, communicating 
with different patient populations, and determining the costs of LS screening to systems and patients [27, 28]. Because 
LS screening has infrequently and inconsistently been implemented across health care settings, there is poor under-
standing of how these contextual factors impede or facilitate implementation of such precision medicine programs in 
health care systems, and under what circumstances [29]. The unique contextual properties of the sites in the HCSRN 
created the opportunity to develop the IMPULSS study to contribute to this understanding.
Capitalizing on the variability and complexity of individual organizational structures and differences in the imple-
mentation of LS screening programs across health care systems, the IMPULSS study will describe and explain individual 
organizational variability. As shown in Table 1, some participating health care systems have implemented programs to 
screen all colorectal cancer (CRC) and endometrial cancer (EC) tumors diagnosed in the system as recommended by cur-
rent guidelines, while others limit to CRC tumors only. Despite the evidence, multiple systems have yet to implement 
any program to systematically screen tumors for LS. This variability across systems will facilitate the identification of 
factors that enable or impede implementation in different organizational contexts. Information gained from this study 
will be used to create a toolkit to guide organizational decision making around implementation and facilitate imple-
mentation of LS screening and other precision medicine programs in health care systems broadly.
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Major Strengths of the HCSRN for D&I Research
The HCSRN is a unique environment for studying the dissemination and implementation of evidence-based practices, 
such as LS screening, because of the number of health care systems in various stages of implementing programs to 
adhere to guidelines. Here we further describe the strengths of the HCSRN for D&I through the themes of 1) a culture 
of collaboration over more than twenty years [30, 31], 2) standardization of data and processes across systems [30, 32], 
and 3) researchers embedded in diverse health care systems [1, 30]. These strengths of the HCSRN are what made it 
possible to develop and fund the IMPULSS project. Below, we describe how each of these major strengths contribute to 
the IMPULSS study and D&I research in general (Table 2).
Culture of collaboration and leveraging methodological expertise
The HCSRN has a long-standing culture of collaboration at the organization, researcher, staff, and research methodol-
ogy levels [30]. Over the past 25 years, member organizations have developed a trust and familiarity that facilitates effi-
cient and effective communication between organizational research administrative staff. Individual researchers have 
established collaborations over this time period across a myriad of research areas to create ongoing research network 
programs and individual research projects [30]. The HCSRN also hosts annual research meetings for sharing research 
findings and lesson learned from one another [31]. The previously mentioned SIGs, including the Genomics SIG, meet 
regularly (http://www.hcsrn.org/en/Collaboration/SIG/) to foster collaboration and facilitate project development 
between HCSRN annual research meetings. There are also qualitative, quantitative, and mixed-methods experts col-
laborating across the HCSRN, as well as senior scientists collaborating to mentor junior researchers through formal 
and informal programs [9, 31]. Specific to the IMPULSS study, the PI had early-career investigator status and utilized 
multiple mentors and senior collaborators within the HCSRN to assist in the process through study design, application 
writing, and the conduct of the project.
Collaboration to build on prior studies: The collaborative culture facilitates the ability of researchers to build on 
studies conducted at one site to inform and contribute to the design of subsequent studies at other sites. This is crucial in 
D&I research to facilitate the adoption of evidence-based practices. For example, a prior study of LS screening implemen-
tation at KPNW assessed patient and provider perspectives of LS screening but was limited to individuals newly diagnosed 
with CRC who had agreed to undergo screening for LS as part of a study protocol at a single site [33, 34]. The IMPULSS 
study was designed to expand these prior results by exploring attitudes of organization stakeholders and patients with 
CRC from health care systems that are and are not screening for LS as part of routine clinical care; rather than being lim-
ited to understanding LS screening only from those patients and providers participating in a study protocol.
Methodologic expertise and collaboration: The robust sharing of research methodology and experiences that has 
been established over time in the HCSRN also enables leveraging expertise and institutional memory of the research-
ers and staff at various sites in the development of new studies within the real-world environment of the health care 
systems. Multiple prior HCSRN studies established the methodology proposed in the IMPULSS study to conduct key 
organizational stakeholder interviews across all participating systems centrally from one site (Geisinger) [35–37]. 
Methodological expertise within the HCSRN is further leveraged for the IMPULSS study as qualitative interviews of 
patients are being conducted centrally for all health care systems from another study location (KPNW) with a robust 
qualitative core and staff experienced at conducting such centralized patient interviews and utilizing well-organized 
processes for tracking and sending incentives [38]. Capitalizing on this expertise to propose centralized interviewing 
facilitates efficient use of study resources and enables a study of this size to be proposed and conducted.
Table 1: Characteristics of Health Care Systems Participating in the IMPULSS Study and Variability in Implementation 
of Programs to Systematically Screen for Lynch Syndrome.
Health Care System System Type HCSRN 
Participant
LS Screening Implementation
Geisinger Member and FFS Yes All CRC and EC
Sutter Health Palo Alto Medical Foundation Member and FFS Yes No Program
Kaiser Permanente Colorado Member only Yes No Program
Kaiser Permanente Northwest Member only Yes All CRC and EC
Meyers Primary Care Member and FFS Yes All CRC
HealthPartners Member and FFS Yes All CRC and EC
Harvard Pilgrim Member and FFS Yes All CRC
Weill Cornell Medical Center FFS only No All CRC and EC
Catholic Health Initiatives FFS only No Variable depending on Hospital location
FFS: Fee for Service; CRC: Colorectal Cancer; EC: Endometrial Cancer.
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Standardization of data and processes across systems
The longevity of the HCSRN provides a wealth of experience in the understanding of data infrastructures and reliabil-
ity and has resulted in robust streamlining of research administrative processes over time. Specific to IMPULSS, this 
familiarity with data infrastructure and existing administrative protocols are another strength of the HCSRN that made 
developing a study of this size possible within the limited research resources available in a funded study.
Data standardization: The common data model utilized by the HCSRN is the Virtual Data Warehouse (VDW) [32]. 
The VDW incorporates several domains related to health care utilization, including demographics, physical measures, 
personal medical history, surgical history, laboratory tests, procedures, prescription medications, diagnoses, and health 
plan claims [39]. For data that are not in the VDW, the collaborative environment of the HCSRN benefits projects that 
require new data elements. In general, genetic data and data related to tumor screening results and other parameters 
important to LS are not easily extracted from electronic data. For the IMPULSS study, multiple site PIs have been work-
ing to determine how to pull laboratory results pertinent to the tumor screening in LS as part of other research. These 
IMPULSS team members also developed approaches to identify newly diagnosed colon cancer, an important study 
population in IMPULSS. These processes leverage site-specific strengths and resources (VDW, tumor registries, or claim-
based algorithms) to identify newly diagnosed cases of colorectal cancer patients, while achieving comparable analytic 
samples and empirical metrics across sites without each site expending resources to develop and validate these algo-
rithms independently. The data parameters required to identify these patients will be used by all participating health 
care systems in IMPULSS to ensure standardization in eligibility criteria and contribute to efficiency in patient recruit-
ment by facilitating electronic identification of eligible patients.
Administrative process streamlining: Over the years, the HCSRN has worked diligently to streamline administra-
tive processes by developing and adopting pre-negotiated sub-award and DUA templates, as well as constructing stand-
ardized IRB templates. These data and organizational standardizations have made it possible to execute DUAs across 
the 7 HCSRN sites and the 2 non-HCSRN sites in the first year of the IMPULSS project. For IRB processes and to facilitate 
movement towards the single IRB process, standard operating procedures (SOPs) for ceding and an Inter-institutional 
authorization agreement (IIA) template for ceding within the HCSRN have existed for some time [30]. Within the 
IMPULSS study, eight sites chose to cede IRB oversight to Geisinger, the lead site. The remaining HCSRN site that did 
not cede was still able to efficiently utilize the Geisinger IRB application to create site-specific IRB documents due to the 
use of standardized IRB templates. The use of HCSRN-approved language for the DUAs and IRB templates provided a 
common starting ground to facilitate study work and recruitment in the first year rather than expending valuable study 
staff time and resources negotiating nine contracts and waiting for nine IRB reviews.
Standardization of data and processes are happening elsewhere and single IRB for multi-site projects funded by the 
NIH is required for projects funded after January 25, 2018 [40]. The HCSRN administrative processes and IRB templates 
for ceding predate the NIH single IRB requirements, giving the HCSRN participating sites more experience in conduct-
ing studies under a single IRB. This also facilitates the process for including non-HCSRN sites in studies or for HCSRN 
sites participating in studies with a non-HCSRN prime site responsible for all IRB administration.
Researchers embedded in diverse health care systems
HCSRN organizations have researchers who are embedded within their respective health care systems and conduct 
research in “real-world” settings critically important to D&I research. These researchers have access to and established 
collaborations with their local clinical enterprises and a deep understanding of the contextual complexity of their 
organization’s data, business model, and organizational and leadership structure.
D&I research in general and the IMPULSS study specifically seeks to understand organizational complexity around 
implementation of evidence-based recommendations. For IMPULSS, the embedded researchers (the site PIs) were able 
to quickly assess specifics related to their organization’s process (or lack thereof) towards implementing universal 
Table 2: The Major Strengths of the HCSRN and Benefits to D&I Research.
HCSRN Strengths Example Benefit to D&I
Culture of Collaboration •	 An atmosphere of shared purpose across all staff levels facilitates research processes
•	 Provides opportunity to adapt processes and interventions implemented at one site to 
other sites and populations
•	 Leverages methodologic expertise at different sites
Standardization of data and  processes 
across systems
•	 A common data model streamlines analyses
•	 Standards for data storage and guidelines for addition of new data facilitate efficient 
cross-site collection and analyses
•	 Established templates for DUAs, IRBs and other research agreements allow efficient 
study management
Researchers embedded in diverse 
health care systems
•	 Embedding researchers in real-world settings facilitates meaningful D&I research
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tumor screening for LS (see above Table 1 – Lynch screening implementation column). This allowed us to develop 
and submit for funding the IMPULSS research project which will significantly contribute to implementation science by 
studying how different organizational contexts contribute to the complexity of implementing evidence-based precision 
medicine programs like LS screening.
Another challenge with D&I studies is that health care systems are rarely static. Because HCSRN investigators are 
embedded in their health care systems, they can notify the larger research team when changes that may impact the 
study happen. Based on experience from other implementation studies conducted by the PI [35, 41], the IMPULSS study 
is designed to keep track of changes impacting LS screening at the external, system, provider, patient, and program 
levels (Table 3).
For IMPULSS, a database is used to track changes to LS screening programs specifically and to clinical and organi-
zational leadership for each health care system within the IMPULSS study. Information is entered into a database as 
reported by site PIs during regular study meetings. Data corresponding to change over time will contribute to study 
results as we identify those contextual factors needed for implementing effective LS screening and other precision 
medicine programs.
Conclusions
Given the importance of conducting research in real world settings to improve patient outcomes, the unique strengths 
of the HCSRN are relevant now more than ever. The development and successful funding of the IMPULSS study is one 
case example of how the strengths of the HCSRN make it an important environment for research on implementing 
evidence-based practices in health care systems. Key strengths of the HCSRN important to D&I research include a cul-
ture of collaboration with high levels of productivity and experience, standardization of data collection and research 
procedures across systems, and researchers embedded in diverse health care systems. These strengths individually are 
not unique to the HCSRN; and in fact, are important to conducting D&I research in any network. Based on the case 
example of the newly-funded IMPULSS precision medicine study, we demonstrate it is the combination of these ele-
ments – collaboration, standardized data and processes – and embedded researchers that make the HCSRN one such 
environment to successfully design and conduct D&I research.
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